Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaojin is a Traditional Chinese Medicine (TCM) formula, often prepared as a capsule or pill, that is widely used in China for its anti-inflammatory, analgesic, and anti-hyperplastic properties. It is traditionally indicated for conditions characterized by "phlegm-dampness" and "blood stasis," which in modern medicine correspond to inflammatory masses, nodules, and hyperplastic diseases. Common indications include breast hyperplasia, thyroid nodules, and gynecological conditions such as endometriosis and associated deep dyspareunia. The formula is a complex mixture of several ingredients, including *Moschus* (musk), *Momordica cochinchinensis*, *Aconitum kusnezoffii*, and various resins and herbs. It is thought to work by improving local microcirculation and reducing the levels of inflammatory mediators.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaojin.